Pazopanib is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma and advanced soft tissue
sarcoma. The authors describe a patient with advanced renal cell carcinoma who developed severe hypertension and severe left
ventricular systolic dysfunction after starting pazopanib therapy with subsequent recovery of left ventricular ejection fraction
upon treatment interruption.

Keywords: Pazopanib, Cardiotoxicity, Heart failure